Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.

Here, based on the highly significant correlation between TP53 mutation and AURKA expression in HCC tissue, the alisertib and lenvatinib combination contributes to the anticancer activity against HCC, caused by combination suppressed cell survival in vitro and tumor growth in vivo.

also in 132,142 other papers